港股異動 | 京東(9618.HK)漲3.65% “雙11”再創佳績 京東健康傳通過上市聆訊
格隆匯11月13日丨隔夜京東(JD.US)於美股市場漲4.27%,京東(9618.HK)今早高開,現漲3.65%,報334.8港元,總市值10478.5億港元。路透旗下IFR引述知情人士透露,京東健康已通過港交所上市聆訊,計劃下週開始上市前推介,預計集資30億美元(約234億港元)。京東健康今年上半年收入87.77億元人民幣,按年飆升76%。經調整盈利為3.71億元人民幣,按年增46%。此外,11月1日-11月11日,京東累計下單金額超2715億元,再次創造了“雙11”新的紀錄。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.